GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
D

Dr Reddy's Laboratories Ltd DRREDDY.NS · INR

Pharmaceuticals · NSE · 🇮🇳 India

Nifty 50

Compare

1,385.00

+0.87%

Close of 9 Nov 2026, in INR

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Dr Reddy's Laboratories Ltd — daily BSE:DRREDDY End of day BSE listing — our prices are the NSE line

Why two exchanges. Dr Reddy's Laboratories Ltd trades on both NSE and BSE. TradingView's free charts don't carry NSE, so the chart shows the BSE listing. The ticker and close we quote are the NSE line.

Market value
₹1.15trn
Last close × shares
Volume
1.9m
Shares, 9 Nov 2026
Price to earnings
26.9
Dividend yield
0.59%

About Dr Reddy's Laboratories Ltd

Its shares trade on NSE under the ticker DRREDDY.NS. It has been listed since 1 January 1986. It is a member of the Nifty 50. In the fiscal year to 31 March 2026, it reported revenue of ₹335.93bn and net income of ₹42.85bn. At that date it held total assets of ₹579.35bn and shareholders' equity of ₹377.06bn.

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. The company is headquartered in Hyderabad, Telangana. The firm operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). PSAI segment includes the Company's business of manufacturing and marketing active pharmaceutical ingredients and intermediates (API) or bulk drugs. Proprietary Products segment focuses on the research, development and manufacture of differentiated formulations and new chemical entities. These products fall within the dermatology and neurology therapeutic areas, and are marketed and sold through its subsidiary, Promius Pharma, LLC.

Figures and description from our data supplier, not checked against the company's own report.

More about Dr Reddy's Laboratories Ltd →

Latest on Dr Reddy's Laboratories Ltd

Our reporting

Next results

22 Jan 2027

Due on 22 Jan 2027. Analysts expect earnings of 11.90 a share.

Other India listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Dr Reddy's Laboratories Ltd's ticker?

Dr Reddy's Laboratories Ltd trades as DRREDDY.NS on NSE, under ISIN INE089A01031.

What was Dr Reddy's Laboratories Ltd's last closing price?

1,385.00 on 9 Nov 2026. The figure is in INR and is never converted.

When does Dr Reddy's Laboratories Ltd next report results?

Results are expected on 22 Jan 2027, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.